Human Peripheral Blood Stem Cells can be a Solution to Diabetes Mellitus Type 2 a Preliminary Study on 14 Patients
Ciro Gargiulo1*, Van H Pham2, Huynh D Thao3, Vo LH Trieu1, Nguyen CD Kieu1, Melvin Shiffman4, Mark J Holtherman5 and Sergey K Aityan6
1HMIC-Tan Tao University, Ho Chi Minh City, Vietnam
2Nam Khoa Bioteck-Tan Tao University, Ho Chi Minh City, Vietnam
3Department of Stem Cell Research, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
4Plastic Surgeon and Stem Cell Specialist Consultant, Tustin CA, USA
5UICOMP, Chicago IL, USA
6Lincoln University, Multidisciplinary Research Center, Oakland CA, USA
- Corresponding Author:
- Ciro Gargiulo
Faculty of Medicine, HMIC-Tan
Tao University, Ho Chi Minh City, Vietnam
Tel: +84 72 3769 216
E-mail: [email protected]
Received Date: July 26, 2016; Accepted Date: August 12, 2016; Published Date: August 19, 2016
Citation: Gargiulo C, Pham VH, Thao HD, Trieu VLH, Kieu NCD, et al. (2016) Human Peripheral Blood Stem Cells can be a Solution to Diabetes
Mellitus Type 2 a Preliminary Study on 14 Patients. J Stem Cell Res Ther 6:354. doi: 10.4172/2157-7633.1000354
Copyright: © 2016 Gargiulo C, et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Background: The use of autologous peripheral stem cell (PB-SCs) in Diabetes Mellitus type 1 (type 1 DM) was described in 2007 with promising conclusion. However a similar treatment with a positive outcome on type 2 diabetes mellitus patients (type 2 DM) has not been yet reported. The goal of this study was to determine the effect of autologous PB-SCs transplantation in treatment of DM2 patient.
Methods: Current study involved 14 patients with type 2 DM (aged 48 to 84 years) during a period of 180 days in our facility. Clinical variables (duration of DM, oral hypoglycemic drugs, time free from oral drugs) and laboratory variables (HbA1c, blood pressure, weight, cholesterol), mononuclear cells infused were assessed. Purified PB SCs were infused into major systemic vein (upper limbs or lower limbs) and subcutaneously in the abdomen. Follow-up is performed weekly after infusion during a period of 6 months.
Results: Mean HbA1c values showed a significant reduction during follow-up in all patients after autologous PB-SCs. After the treatment with stem cells the HbA1c level dropped by at least one unit relative to the HbA1c level in the medication phase, with stem cells patients have mean value of HbA1c lower than 6.5% (Mean value at time of diagnose 8.9%, at time of medication 7.9% and at time of post stem cell therapy 6.2%). Also, it was confirmed that the stem cell treatment is more efficient for the patients with higher HbA1c level in the medication phase and the level originally diagnosed. In 180 days after the combined therapy, HbA1c, cholesterol, and liver profile stay stable compare to the baseline among those patients who did not continue the LGI diet. All patients were insulin and/or oral hypoglycemic drugs completely free.
Conclusions: Therapy based on autologous PB-SCs can improve glucose control and reduce the dose of insulin and/or oral hypoglycemic drugs in type 2 DM patients, but it only improves pancreatic β-cell function transiently if the patients would not adjust their diet and life style. Further randomized controlled clinical trials involving more patients will be required to confirm these findings and the mechanism needs to be learned deeper.